SCHEDULE: Universe Pharmaceuticals: Ownership Threshold Update

Star Voyage International Limited and Xuncheng Chen report a combined beneficial ownership of 9.94% in Universe Pharmaceuticals INC's Class A ordinary shares.

Summary

• Star Voyage International Limited, a company wholly owned by Xuncheng Chen, now beneficially owns 497,917 Class A ordinary shares of Universe Pharmaceuticals INC.
• This represents 9.94% of the total outstanding Class A ordinary shares.
• The filing is a Schedule 13G, indicating a passive investment stake.
• The total number of outstanding shares as of July 27, 2026, was 5,008,313.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership to just under the 10% threshold, without providing new operational or financial performance data.

Positives

• The filing clarifies the beneficial ownership structure for a significant block of shares.
• The ownership level of 9.94% is just below the 10% threshold that would trigger more stringent reporting requirements.

Negatives

• The filing does not provide any new financial performance data or operational updates for Universe Pharmaceuticals INC.
• It solely reports a change in beneficial ownership, offering no insight into the company's strategic direction or health.

Risks

• While the filing indicates a passive investment, any significant shift in this ownership stake could impact the company's stock price.
• The concentration of nearly 10% ownership in a single entity could potentially influence corporate governance decisions if that entity decides to become more active.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it is a disclosure of beneficial ownership.

Management Comments

• Star Voyage International Limited is wholly owned and controlled by Xuncheng Chen, an individual.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders who acquire more than 5% of a company's voting stock. This filing indicates a passive investment strategy by Star Voyage International Limited and Xuncheng Chen in the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant ownership block, which can be reassuring. However, it does not offer new information to directly impact investment decisions.
• Management: The filing confirms a passive investment, suggesting no immediate threat of a hostile takeover or activist involvement from these holders.

Next Steps

• Continue to monitor Universe Pharmaceuticals INC's filings for any further changes in beneficial ownership or operational updates.
• Observe if Star Voyage International Limited or Xuncheng Chen increase their stake beyond the 10% threshold, which would necessitate a Schedule 13D filing.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Class A ordinary shares, Star Voyage International Limited, Xuncheng Chen, Universe Pharmaceuticals INC, shareholder, investment